The UK’s drug watchdog is reconsidering two Alzheimer’s disease medicines after rejecting them for being too expensive. The National Institute for Health and Care Excellence

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.

The assets managed by Novo Holdings, the controlling shareholder of Novo Nordisk, fell by some 35% last year. But that doesn’t mean it will rein

Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.